[go: up one dir, main page]

WO2009030224A3 - Novel quinazoline compounds and the use thereof for treating cancerous diseases - Google Patents

Novel quinazoline compounds and the use thereof for treating cancerous diseases Download PDF

Info

Publication number
WO2009030224A3
WO2009030224A3 PCT/DE2008/001528 DE2008001528W WO2009030224A3 WO 2009030224 A3 WO2009030224 A3 WO 2009030224A3 DE 2008001528 W DE2008001528 W DE 2008001528W WO 2009030224 A3 WO2009030224 A3 WO 2009030224A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancerous diseases
quinazoline compounds
treating cancerous
novel quinazoline
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2008/001528
Other languages
German (de)
French (fr)
Other versions
WO2009030224A2 (en
Inventor
Hans Scheefers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ScheBo Biotech AG
Original Assignee
ScheBo Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200810012435 external-priority patent/DE102008012435A1/en
Application filed by ScheBo Biotech AG filed Critical ScheBo Biotech AG
Publication of WO2009030224A2 publication Critical patent/WO2009030224A2/en
Publication of WO2009030224A3 publication Critical patent/WO2009030224A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds of general formula (I) with -C-O-N- or -C-N-O- groups (for example -C-O-N(H)-C(=O)- or -C-N(H)-O-C(=O)-), to methods for the production thereof, and to the use of same in medical treatment, especially for cancerous diseases.
PCT/DE2008/001528 2007-09-07 2008-09-08 Novel quinazoline compounds and the use thereof for treating cancerous diseases Ceased WO2009030224A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE102007044564 2007-09-07
DE102007044564.6 2007-09-07
DE102008012435.4 2008-02-29
DE200810012435 DE102008012435A1 (en) 2008-02-29 2008-02-29 New quinazoline compounds are tyrosin-kinase inhibitors e.g. to treat cancer, hematologic or solid tumors, non-Hodgkin tumors or T-cell lymphoma; and for the modulation of the cell cycle, cell differentiation, apoptosis or angiogenesis
DE102008045244.0 2008-08-29
DE102008045244 2008-08-29

Publications (2)

Publication Number Publication Date
WO2009030224A2 WO2009030224A2 (en) 2009-03-12
WO2009030224A3 true WO2009030224A3 (en) 2009-08-13

Family

ID=40361674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2008/001528 Ceased WO2009030224A2 (en) 2007-09-07 2008-09-08 Novel quinazoline compounds and the use thereof for treating cancerous diseases

Country Status (1)

Country Link
WO (1) WO2009030224A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019852A1 (en) 2009-05-06 2010-11-11 Schebo Biotech Ag New polymer compound comprising amine structural elements, useful as synthetic resins, coatings, foams, liquid crystals, adhesives, paints, varnishes, composite materials, in cosmetics, and in polymer electronics
PL2611300T3 (en) 2010-09-03 2016-10-31 Substituted annelated dihydropyrimidinone compounds
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2019071351A1 (en) * 2017-10-12 2019-04-18 Trillium Therapeutics Inc. Novel fluorinated 4-aryloxyquinazoline derivatives as egfr inhibitors useful for treating cancers
CN107840843A (en) * 2017-10-17 2018-03-27 浙江工业大学义乌科学技术研究院有限公司 A kind of synthetic method of AZD2171 intermediate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038983A1 (en) * 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
WO2001012604A1 (en) * 1999-08-18 2001-02-22 Aventis Cropscience Gmbh Fungicides
WO2001021594A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
EP1110953A1 (en) * 1995-03-30 2001-06-27 Pfizer Inc. Quinazoline derivatives
EP1510221A1 (en) * 2002-06-03 2005-03-02 Mitsubishi Pharma Corporation Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr
EP1553097A1 (en) * 1999-02-10 2005-07-13 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110953A1 (en) * 1995-03-30 2001-06-27 Pfizer Inc. Quinazoline derivatives
WO1997038983A1 (en) * 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
EP1553097A1 (en) * 1999-02-10 2005-07-13 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore
WO2001012604A1 (en) * 1999-08-18 2001-02-22 Aventis Cropscience Gmbh Fungicides
WO2001021594A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
EP1510221A1 (en) * 2002-06-03 2005-03-02 Mitsubishi Pharma Corporation Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr

Also Published As

Publication number Publication date
WO2009030224A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2009030224A3 (en) Novel quinazoline compounds and the use thereof for treating cancerous diseases
WO2009050506A3 (en) Combination 059
WO2009011850A3 (en) Novel therapeutic compounds
UA98125C2 (en) Substituted dihydropyrazolon for the treatment of cardiovascular and haematological diseases
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
UA102251C2 (en) Aminidihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
EA201200473A1 (en) SUBSTITUTED (HETEROARILMETHYL) THIOGIDANTOINES
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
WO2009074827A3 (en) Combination comprising a mek inhibitor and an aurora kinase inhibitor
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2008138904A3 (en) Rna antagonist compounds for the modulation of her3
MY186456A (en) Quinazoline carboxamide azetidines
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ZA200610640B (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2010121675A3 (en) Thiazolyl-benzimidazoles
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2004087700A8 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 08801321

Country of ref document: EP

Kind code of ref document: A2